The tumour antigens RAGE-1 and MGEA6 are expressed more frequently in the less lineage restricted subgroups of presentation acute myeloid leukaemia

Guinn, Barbara-ann, Gilkes, Amanda F., Mufti, Ghulam I., Burnett, Alan K. and Mills, Ken I. (2006) The tumour antigens RAGE-1 and MGEA6 are expressed more frequently in the less lineage restricted subgroups of presentation acute myeloid leukaemia. British Journal of Haematology, 134 (2), 238-239. (doi:10.1111/j.1365-2141.2006.06135.x).

Abstract

We have analysed the frequency of present calls for RAGE-1 and MGEA6 in patients based on FAB subclass. MGEA6 and RAGE-1 present calls were significantly higher in the M0/M1/M2 versus the M3/M4/M5/M6/M7 groups for both RAGE-1 (p<0.0001) and MGEA6 (p<0.0001). However dividing patients into three WHO subgroups as follows (i) ‘recurrent’ representing acute myeloid leukaemia with recurrent genetic abnormalities, (ii) ‘AML’ representing acute myeloid leukaemia, minimally differentiated; acute myeloid leukaemia without maturation; acute myeloid leukaemia with maturation broadly representing FAB M0, M1 and M2 and (iii) ‘lineage’ representing acute myelomonocytic leukaemia; acute monoblastic leukaemia; acute erythroid leukaemia (erythroid/myeloid and pure erythroid leukaemia); acute megakaryoblasic leukaemia and acute basophilic leukaemia broadly representing FAB M4 – M7 indicated that a significant number of patients in the AML group had MGEA6 present calls compared with patients in the lineage and recurrent groups (p=0.0185). However RAGE-1 expression did not segregate based on WHO this grouping. We examined whether in our patients population the M0/1/2 FAB subgroups were associated with a poorer survival rate than M3/4/5/6/7 and this was not found to be the case (p=0.27). RAGE-1 and MGEA6 present calls were also not found to be associated with poorer survival (p=0.891 and 0.956, respectively). RAGE-1 present calls did not to segregate with any single cytogenetic risk group (good, standard or poor). However using Chi2 pairwise comparisons the frequency of MGEA6 present calls in good versus poor, good versus standard and standard versus poor cytogenetic risk groups were all highly significant (each p<0.0001). This is the first study to suggest a differential expression of a CT antigen based on FAB or WHO subgroup or cytogenetic risk group. In addition, MGEA6 and RAGE-1 may provide suitable targets for the immunotherapy of AML particularly for patients in the M0, M1 and M2 subgroups

This record has no associated files available for download.

Contributors

Download statistics